PTEN signaling in brain: neuropathology and tumorigenesis

被引:187
作者
Endersby, R. [1 ]
Baker, S. J. [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA
基金
美国国家卫生研究院;
关键词
PTEN; PI3; kinase; tumor suppressor; brain; glioblastoma;
D O I
10.1038/onc.2008.239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor that antagonizes the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway by functioning as a lipid phosphatase. This ubiquitous and evolutionarily conserved signaling cascade influences numerous functions including cell growth, survival, proliferation, migration and metabolism. Inherited mutations in PTEN cause pleiotropic effects including cancer predisposition as well as a range of neurological abnormalities revealing specialized roles for PTEN in nervous system development and maintenance. Somatic mutations in PTEN occur frequently as late events in sporadic brain tumors. Mouse models based on Pten deletion in the brain have provided insights into the normal functions of Pten in the nervous system as well as the initiation and progression of gliomas. Compromised PTEN function may contribute to gliomagenesis through disrupted regulation of proliferation, migration, invasion, angiogenesis, stem cell self-renewal and regulation of other tumor suppressor pathways such as p53. Clinical findings in high-grade glioma suggest that PTEN gene alterations are associated with poor prognosis and may influence response to specific therapies. Emerging research using specific pharmacological inhibitors of the PI3K pathway may provide novel therapeutic options for the treatment of PTEN-deficient tumors.
引用
收藏
页码:5416 / 5430
页数:15
相关论文
共 152 条
  • [1] Lhermitte-Duclos disease: A report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway
    Abel, TW
    Baker, SJ
    Fraser, MM
    Tihan, T
    Nelson, JS
    Yachnis, AT
    Bouffard, JP
    Mena, H
    Burger, PC
    Eberhart, CG
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (04) : 341 - 349
  • [2] Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha
    Alessi, DR
    James, SR
    Downes, CP
    Holmes, AB
    Gaffney, PRJ
    Reese, CB
    Cohen, P
    [J]. CURRENT BIOLOGY, 1997, 7 (04) : 261 - 269
  • [3] Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease
    Backman, SA
    Stambolic, V
    Suzuki, A
    Haight, J
    Elia, A
    Pretorius, J
    Tsao, MS
    Shannon, P
    Bolon, B
    Ivy, GO
    Mak, TW
    [J]. NATURE GENETICS, 2001, 29 (04) : 396 - 403
  • [4] PTEN methylation and expression in glioblastomas
    Baeza, N
    Weller, M
    Yonekawa, Y
    Kleihues, P
    Ohgaki, H
    [J]. ACTA NEUROPATHOLOGICA, 2003, 106 (05) : 479 - 485
  • [5] Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 56 kinase in vivo at Thr-412 as well as Thr-252
    Balendran, A
    Currie, R
    Armstrong, CG
    Avruch, J
    Alessi, DR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (52) : 37400 - 37406
  • [6] Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    Bao, Shideng
    Wu, Qiulian
    McLendon, Roger E.
    Hao, Yueling
    Shi, Qing
    Hjelmeland, Anita B.
    Dewhirst, Mark W.
    Bigner, Darell D.
    Rich, Jeremy N.
    [J]. NATURE, 2006, 444 (7120) : 756 - 760
  • [7] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS
    BELLACOSA, A
    DEFEO, D
    GODWIN, AK
    BELL, DW
    CHENG, JQ
    ALTOMARE, DA
    WAN, MH
    DUBEAU, L
    SCAMBIA, G
    MASCIULLO, V
    FERRANDINA, G
    PANICI, PB
    MANCUSO, S
    NERI, G
    TESTA, JR
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) : 280 - 285
  • [8] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
    Bianco, R
    Shin, I
    Ritter, CA
    Yakes, FM
    Basso, A
    Rosen, N
    Tsurutani, J
    Dennis, PA
    Mills, GB
    Arteaga, CL
    [J]. ONCOGENE, 2003, 22 (18) : 2812 - 2822
  • [9] Cytogenetics and Molecular Genetics of Malignant Gliomas and Medulloblastoma
    Bigner, Sandra H.
    Vogelstein, Bert
    [J]. BRAIN PATHOLOGY, 1990, 1 (01) : 12 - 18
  • [10] The TOR pathway: A target for cancer therapy
    Bjornsti, MA
    Houghton, PJ
    [J]. NATURE REVIEWS CANCER, 2004, 4 (05) : 335 - 348